AstraZeneca's Elecoglipron Phase 2 Data Intensifies Oral GLP-1 Competition, Exposing Gaps in Long-Term Efficacy and Pricing Strategies

AstraZeneca's mid-stage VISTA and SOLSTICE trials, published in The Lancet as randomized controlled studies, provide the first oral GLP-1 data from a major pharma beyond Lilly, yet the STAT coverage underplays cross-trial comparability issues and omits sponsor conflicts inherent in industry-funded Phase 2 work with modest sample sizes typical of this stage. VISTA showed 11.2% weight loss at 36 weeks in obesity patients on highest-dose elecoglipron, matching Lilly's orforglipron Phase 3 results only superficially since the latter spanned 72 weeks with larger cohorts. SOLSTICE demonstrated superior A1C reductions versus open-label oral semaglutide, but lacks the head-to-head rigor of Novo Nordisk's longer-term oral data. This signals pricing ripple effects as multiple orals erode injectable dominance in diabetes care, potentially spurring value-based models while exposing adherence gaps in real-world observational extensions. Missed by initial reporting: how this accelerates generic pathways and pressures payers amid rising obesity prevalence.